Pfizer Inc
$221.99B- Market cap
- $158.34B
- Debt
- +$64.80B
- Cash
- −$1.14B
Capital structure 71% equity / 29% debt · EV / Revenue 3.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $158.34B · View financials
Snapshot Sep 9, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: PFE stock price at discount vs DHR $27.78 current versus $55.17 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Implied fair value · at PFE's multiple
Snapshot Sep 9, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 71% equity / 29% debt · EV / Revenue 3.55x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 89% equity / 11% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$12.82
Base
$16.23
Bull
$22.30
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
AGILENT TECHNOLOGIES, INC.
PFE vs A
ILLUMINA, INC.
PFE vs ILMN
ABBOTT LABORATORIES
PFE vs ABT
LOEWS CORP
PFE vs L
BERKSHIRE HATHAWAY INC
PFE vs BRK-B
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can re-accelerate growth and sustain margins without increasing leverage, then a selective long position may make sense because the stock trades well below DHR on every major valuation multiple; otherwise, the current discount appears consistent with weaker growth and quality.
PFE trades at a clear discount to DHR across P/E, P/S, EV/EBITDA, and EV/Revenue, while the model-implied price suggests meaningful upside only if PFE can re-rate toward DHR-like multiples. However, PFE also sits much closer to its historical and DCF ranges than to DHR-implied range, which tempers the valuation gap.
Supporting Metrics